{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:17:15Z","timestamp":1790709435420,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP 22ek0410098"],"award-info":[{"award-number":["JP 22ek0410098"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08279"],"award-info":[{"award-number":["22K08279"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.alit.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T18:46:52Z","timestamp":1667328412000},"page":"31-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatments of refractory eosinophilic lung diseases with biologics"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-3061","authenticated-orcid":false,"given":"Koichiro","family":"Asano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-9791","authenticated-orcid":false,"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kamide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2022.10.004_bib1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF02079221","article-title":"Zur differential-diagnose der Lungeninfiltrierungen II","volume":"79","author":"L\u00f6ffler","year":"1932","journal-title":"Beitr\u00e4ge zur Klinik der Tuberkulose"},{"key":"10.1016\/j.alit.2022.10.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.7.1.1","article-title":"Pulmonary eosinophilia","volume":"7","author":"Crofton","year":"1952","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2022.10.004_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.7326\/0003-4819-36-5-1217","article-title":"Pulmonary infiltration with eosinophilia (PIE syndrome)","volume":"36","author":"Reeder","year":"1952","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.alit.2022.10.004_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00005792-196907000-00001","article-title":"The eosinophilic pneumonias","volume":"48","author":"Liebow","year":"1969","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.alit.2022.10.004_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM196904102801501","article-title":"Chronic eosinophilic pneumonia","volume":"280","author":"Carrington","year":"1969","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJM198908313210903","article-title":"Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure","volume":"321","author":"Allen","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1398-9995.2005.00812.x","article-title":"Eosinophilic pneumonias","volume":"60","author":"Cottin","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib8","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccm.2016.04.015","article-title":"Eosinophilic lung diseases","volume":"37","author":"Cottin","year":"2016","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.alit.2022.10.004_bib10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.alit.2017.12.004","article-title":"Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: a review of the previous literature","volume":"67","author":"Suzuki","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","article-title":"Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management","volume":"68","author":"Suzuki","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00408-017-0048-8","article-title":"Possible role of IL-25 in eosinophilic lung inflammation in patients with chronic eosinophilic pneumonia","volume":"195","author":"Katoh","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.alit.2022.10.004_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1398-9995.2004.00492.x","article-title":"Elevated interleukin-18 levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia","volume":"59","author":"Katoh","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1183\/09031936.01.17509620","article-title":"Eotaxin and monocyte chemoattractant protein-1 in chronic eosinophilic pneumonia","volume":"17","author":"Tateno","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.10.004_bib15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1183\/09031936.00199614","article-title":"Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia","volume":"45","author":"Oyama","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.10.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2017.08.009","article-title":"Persistent impairment on spirometry in chronic eosinophilic pneumonia: a longitudinal observation study (Shizuoka-CEP study)","volume":"119","author":"Suzuki","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00005792-199809000-00001","volume":"77","author":"Marchand","year":"1998","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.alit.2022.10.004_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/JAA.S343272","article-title":"Anti-IL-5 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a case series","volume":"15","author":"Tashiro","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.10.004_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.alit.2022.10.004_bib22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.anai.2021.02.016","article-title":"Relapsing chronic eosinophilic pneumonia treated successfully with Benralizumab","volume":"126","author":"Ricketti","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.810","article-title":"Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection","volume":"9","author":"Takano","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.alit.2022.10.004_bib24","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-5-3","article-title":"Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance","volume":"9","author":"Kisling","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.alit.2022.10.004_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.alit.2020.07.005","article-title":"Benralizumab as initial treatment for chronic eosinophilic pneumonia","volume":"70","author":"Yazawa","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib26","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1016\/j.jaip.2020.06.053","article-title":"Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: a case report","volume":"8","author":"Ciuffreda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib27","article-title":"Rapid and sustained effects of a single dose of Benralizumab on chronic eosinophilic pneumonia","volume":"30","author":"Izumo","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.alit.2022.10.004_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-2035","article-title":"Can omalizumab be effective in chronic eosinophilic pneumonia?","volume":"143","author":"Domingo","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.10.004_bib29","article-title":"A\u00a0case of chronic eosinophilic pneumonia successfully treated with mepolizumab","volume":"6","author":"To","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib30","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib31","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.jaip.2021.02.042","article-title":"Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.alit.2022.03.005","article-title":"Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: il-5-driven pathology?","volume":"71","author":"Nishiyama","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061105","article-title":"Diagnostic performance of various tests and criteria employed in allergic bronchopulmonary aspergillosis: a latent class analysis","volume":"8","author":"Agarwal","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2022.10.004_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.alit.2017.04.011","article-title":"Allergic bronchopulmonary aspergillosis in Japan: a nationwide survey","volume":"67","author":"Oguma","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/1040841X.2012.754401","article-title":"Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview","volume":"40","author":"Chowdhary","year":"2014","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.alit.2022.10.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.08.029","article-title":"New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation","volume":"147","author":"Asano","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1183\/13993003.01475-2015","article-title":"A\u00a0randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"47","author":"Agarwal","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.10.004_bib39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A\u00a0randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib40","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","article-title":"A\u00a0randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"153","author":"Agarwal","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.10.004_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01159-2018","article-title":"A\u00a0randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"52","author":"Agarwal","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.10.004_bib42","doi-asserted-by":"crossref","first-page":"2101787","DOI":"10.1183\/13993003.01787-2021","article-title":"A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"59","author":"Agarwal","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.10.004_bib43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1378\/chest.130.2.442","article-title":"Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India","volume":"130","author":"Agarwal","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.10.004_bib44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21911\/aai.476","article-title":"Allergic bronchopulmonary aspergillosis: a clinical evaluation of 15 patients and successful omalizumab treatment of five patients","volume":"17","author":"\u00dcnal","year":"2019","journal-title":"Asthma Allergy Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib45","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center\u2019s experience with 14 cases","volume":"36","author":"Ayd\u0131n","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.alit.2022.10.004_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000507216","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis complicated by chronic bacterial infection in the airways","volume":"181","author":"Tomomatsu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2022.10.004_bib50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.alit.2018.03.004","article-title":"Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"67","author":"Oda","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12890-018-0617-5","article-title":"A\u00a0case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"18","author":"Terashima","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.alit.2022.10.004_bib52","first-page":"59","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: case report and review of the literature","volume":"26","author":"Hirota","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.alit.2022.10.004_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","article-title":"Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab","volume":"68","author":"Soeda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib54","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib55","article-title":"Real-world effectiveness of anti-IL-5\/5R therapy in severe atopic eosinophilic asthma with fungal sensitization","volume":"9","author":"Dhariwal","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib56","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejim.2021.12.026","article-title":"One-year mepolizumab for allergic bronchopulmonary aspergillosis: focus on steroid sparing effect and markers of response","volume":"99","author":"Caminati","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.alit.2022.10.004_bib58","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18176\/jiaci.0564","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with benralizumab in a patient who did not respond to omalizumab","volume":"30","author":"Bernal-Rubio","year":"2020","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib59","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jaip.2018.11.024","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with Benralizumab","volume":"7","author":"Soeda","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib60","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with Benralizumab treatment","volume":"69","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"M\u00fcmmler","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib62","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib63","doi-asserted-by":"crossref","first-page":"omaa029","DOI":"10.1093\/omcr\/omaa029","article-title":"Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis","volume":"2021","author":"Ali","year":"2021","journal-title":"Oxf Med Case Reorts"},{"key":"10.1016\/j.alit.2022.10.004_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.alit.2020.08.006","article-title":"Efficacy of dupilumab and biomarkers for systemic corticosteroid naive allergic bronchopulmonary mycosis","volume":"70","author":"Tashiro","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12081","article-title":"Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab","volume":"11","author":"van der Veer","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000050518","article-title":"Chronic bronchiolitis with associated eosinophilic lung disease (eosinophilic bronchiolitis)","volume":"68","author":"Takayanagi","year":"2001","journal-title":"Respiration"},{"key":"10.1016\/j.alit.2022.10.004_bib67","first-page":"229","article-title":"[Eosinophilic bronchiolitis]","volume":"40","author":"Takaku","year":"2021","journal-title":"Kokyuki Naika [Respir Med]"},{"key":"10.1016\/j.alit.2022.10.004_bib68","first-page":"628","article-title":"[Bronchiolitis]","volume":"21","author":"Nagase","year":"2014","journal-title":"Arerugi Men-eki [Allergy Immunol]"},{"key":"10.1016\/j.alit.2022.10.004_bib69","first-page":"53","article-title":"[Pathology and treatment of eosinophilic bronchiolitis]","volume":"5018","author":"Kurashima","year":"2020","journal-title":"Nihon Iji Shinpo [Jpn Med J]"},{"key":"10.1016\/j.alit.2022.10.004_bib70","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1183\/09031936.00099812","article-title":"Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome","volume":"41","author":"Cordier","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.10.004_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.397","article-title":"Anti-interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis","volume":"7","author":"Tomyo","year":"2019","journal-title":"Respirol Case Rep"},{"issue":"Suppl 128","key":"10.1016\/j.alit.2022.10.004_bib72","first-page":"11","article-title":"Cottin VEvolution from hypereosinophilic bronchiolitis to eosinophilic granulomatosis with polyangiitis following COVID-19: a case report","volume":"39","author":"Merveilleux du Vignaux","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1542\/hpeds.2020-0123","article-title":"COVID-19 and Kawasaki disease: novel virus and novel case","volume":"10","author":"Jones","year":"2020","journal-title":"Hosp Pediatr"},{"key":"10.1016\/j.alit.2022.10.004_bib74","first-page":"1235","article-title":"[Two Cases of eosinophilic bronchiolitis whom successfully treated with omalizumab]","volume":"58","author":"Sato","year":"2009","journal-title":"Arerugi [Jpn J Allergol]"},{"key":"10.1016\/j.alit.2022.10.004_bib75","first-page":"214","article-title":"[A case of severe bronchial asthma and eosinophilic bronchiolitis treated with omalizumab]","volume":"9","author":"Taba","year":"2011","journal-title":"Nihon Shouni Nanchi Zensoku Arerugi Shikkan Gakkaishi [Jpn J Pediatr Intractable Asthma Allergic Dis]"},{"key":"10.1016\/j.alit.2022.10.004_bib76","first-page":"287","article-title":"[A case of eosinophilic bronchiolitis responded well to anti-IL-5 antibody treatment]","volume":"7","author":"Ueda","year":"2018","journal-title":"Nihon Kokyuki Gakkaishi [Ann Jpn Respir Soc]"},{"key":"10.1016\/j.alit.2022.10.004_bib77","article-title":"Eosinophilic bronchiolitis successfully treated with mepolizumab","volume":"8","author":"Takeshita","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib78","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaip.2021.10.064","article-title":"Pediatric eosinophilic bronchiolitis successfully treated with mepolizumab","volume":"10","author":"Arceri","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-246058","article-title":"Eosinophilic bronchiolitis successfully treated with Benralizumab","volume":"14","author":"Sugino","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.alit.2022.10.004_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus Conference Nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.alit.2022.10.004_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.10.004_bib82","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/art.41727","article-title":"Eosinophil ETosis-mediated release of Galectin-10 in eosinophilic granulomatosis with polyangiitis","volume":"73","author":"Fukuchi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib83","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Sabl\u00e9-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.alit.2022.10.004_bib84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","article-title":"Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome","volume":"63","author":"Lanham","year":"1984","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.alit.2022.10.004_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"American College of Rheumatology\/European alliance of associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.alit.2022.10.004_bib86","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib87","doi-asserted-by":"crossref","first-page":"m421","DOI":"10.1136\/bmj.m421","article-title":"Management of ANCA associated vasculitis","volume":"368","author":"Wallace","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.alit.2022.10.004_bib88","doi-asserted-by":"crossref","first-page":"00311","DOI":"10.1183\/23120541.00311-2019","article-title":"Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Kent","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.alit.2022.10.004_bib89","article-title":"Novel targets for drug use in eosinophilic granulomatosis with polyangiitis","volume":"8","author":"Uzzo","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.alit.2022.10.004_bib90","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.alit.2022.10.004_bib91","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.alit.2022.10.004_bib92","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib93","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.alit.2022.10.004_bib94","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2022.10.004_bib96","first-page":"752","article-title":"Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial","volume":"262","author":"Koike","year":"2015","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.alit.2022.10.004_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.alit.2022.10.004_bib98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.alit.2022.10.004_bib99","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib100","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roab005","article-title":"Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis","volume":"32","author":"Nakamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib102","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.10.004_bib104","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.10.004_bib107","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.alit.2022.10.004_bib108","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"Suppl 124","key":"10.1016\/j.alit.2022.10.004_bib109","first-page":"214","article-title":"Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review","volume":"38","author":"Basta","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib110","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.alit.2022.10.004_bib111","article-title":"Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab","volume":"8","author":"Galant-Swafford","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.10.004_bib112","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.alit.2022.10.004_bib113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2022.10.004_bib114","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:13:44Z","timestamp":1761156824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893022001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1323893022001216"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2022.10.004","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments of refractory eosinophilic lung diseases with biologics","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Allergology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}